Drug May Help Overcome Chemo Resistance in Ovarian Cancer

Professor John Hooper. Credit: Mater Research

Scientists from Mater Research – The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

Led by Professor John Hooper, the TRI-based Mater Research team collaborated with researchers from the Queensland University of Technology (QUT) and the Mayo Clinic in the United States of America. In a pre-clinical study, they found that the drug, 2-deoxy-D-glucose, could be used at very low levels to significantly improve the effectiveness of chemotherapy in treating clear cell ovarian cancer tumour cells.

Their work, which was published in the prestigious international journal Cancers, provides the rationale for a clinical trial to evaluate the use of low-dose 2-deoxy-D-glucose in treating patients with this type of cancer, according to Professor Hooper.

“Ovarian clear cell carcinoma is a type of ovarian cancer associated with poor prognosis and resistance to chemotherapy,” he said.

“Our pre-clinical work used cells taken from patient tumours, so we were very encouraged that we could use such a low dose of 2-deoxy-D-glucose to overcome the chemotherapy resistance and stop tumour growth.

“This drug has been trialled previously in other cancers, but we were able to use a 10-fold lower dose than previously reported so that it’s safer for patients and is less likely to cause side-effects.”

The team is hoping to begin trialling the treatment combination in patients within the next 12 months, following the announcement they had received an award to progress the ovarian cancer research.

The peak, national gynaecological cancer clinical trials organisation for Australia and New Zealand, ANZGOG, awarded the team its Fund for New Research 2019 – Judith Meschke Memorial Grant to study whether “modulation of metabolism can improve the effectiveness of chemotherapy for clear cell ovarian cancer”.

Professor Hooper gratefully acknowledged the generosity of the ANZGOG funding from a bequest of Judith Meschke.

“The involvement in the project of so many talented people, scientists and clinicians, is in the spirit of the creative process fostered by the diverse and talented Australian arts community exemplified by the achievements of Ms Meschke.”

Reference: Khan, et al. (2020) Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. Cancers DOI: https://doi.org/10.3390/cancers12040869

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

This article was published by Technology Networks.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to Home